AKBC w/ the BenevolentAI team

BenevolentAI is proud to sponsor the AKBC conference, which will be held in London 3-5 November at the Barbican Centre.

Catch the BenevolentAI team at AKBC, where they will present their latest paper on Pseudo-Riemannian Embedding Models for Multi-Relational Graph Representations.

Link to the conference → 


Pseudo-Riemannian Embedding Models for Multi-Relational Graph Representations

Authors: Saee Gopal Paliwal, Angus Brayne, Benedek Fabian, Maciej Wiatrak, Aaron Sim.

In this paper we generalize single-relation pseudo-Riemannian graph embedding models to multi-relational networks, and show that the typical approach of encoding relations as manifold transformations translates from the Riemannian to the pseudo-Riemannian case. In addition we construct a view of relations as separate spacetime submanifolds of multi-time manifolds, and consider an interpolation between a pseudo-Riemannian embedding model and its Wick-rotated Riemannian counterpart. We validate these extensions in the task of link prediction, focusing on flat Lorentzian manifolds, and demonstrate their use in both knowledge graph completion and knowledge discovery in a biological domain.

Link to the paper → 
More Posts

You Might Also Like

Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022